1. Scrip
  2. >>R&D
  3. >>Clinical Trials

What To Look Out For At ESC 2024

 
• By Elizabeth Cairns

Full data on heart disease products from Alnylam, Bayer and others will take center stage at the cardiology meeting later this month.    

Autumn red leaf with cut heart in a hand - Image

The past year has seen several high-profile Phase III cardiology successes toplined by various biopharma firms – and at least one disaster. The annual congress of the European Society of Cardiology (ESC), which takes place in London, UK, from 30 August-2 September, will provide a chance to engage with the data in more depth.

Key Takeaways
  • The annual meeting of the European Society of Cardiology is approaching and will see several intriguing and commercially significant presentations.
  • Three Hot Line sessions, covering Alnylam’s Amvuttra...

One of the coveted Hot Line slots, in the very first of these sessions, has been taken by the HELIOS-B trial of Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran) in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from R&D